Current status and clinical outcome of endoscopic hemostatic powder in gastrointestinal bleeding: a retrospective multicenter study
Clinical Endoscopy · 30.09.2024 · 57 (5) · 620-627
DOI: 10.5946/ce.2023.179 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Endoscopy, erschienen am 30.09.2024. Verfasst von Zie Hae Lim und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Korean Gastrointestinal Endoscopy Research Foundation.
Abstract (Originalsprache)
Background/Aims: Few multicenter studies have investigated the efficacy of hemostatic powders in gastrointestinal (GI) bleeding. We aimed to investigate the clinical outcomes of hemostatic powder therapy and the independent factors affecting rebleeding rates.
Methods
We retrospectively recruited patients who underwent a new hemostatic adhesive powder (UI-EWD; Next-Biomedical) treatment for upper and lower GI bleeding between January 1, 2020 and March 1, 2023. We collected patients’ medical records and bleeding lesions. The primary outcomes were clinical and technical success rates, and the secondary outcomes were early, delayed, and refractory bleeding, mortality, and factors affecting early rebleeding rates.
Results
This study enrolled 135 patients (age: 67.7±13.6 years, male: 74.1%) from five hospitals. Indications for UI-EWD were peptic ulcers (51.1%), post-procedure-related bleeding (23.0%), and tumor bleeding (19.3%). The clinical and technical success rates were both 97%. The early, delayed, and refractory rebleeding rates were 19.3%, 11.1%, and 12.8%, respectively. Initially elevated blood urea nitrogen (BUN) levels (p=0.014) and Forrest classification IA or IB compared with IIA or IIB (p=0.036) were factors affecting early rebleeding.
Conclusions
UI-EWD showed high clinical and technical success rates; however, rebleeding after UI-EWD therapy in patients with initially high BUN levels and active bleeding, according to the Forrest classification, should be considered.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea.
- Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea.
- Division of Gastroenterology, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea.
- Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
- Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Förderung
- Korean Gastrointestinal Endoscopy Research Foundation
Zitieren
APA
Lim, Z. H., Seo, S. I., Myung, D. S., Kim, S. H., Lee, H. H., Kim, S., & Lee, B. I. (2024). Current status and clinical outcome of endoscopic hemostatic powder in gastrointestinal bleeding: a retrospective multicenter study. Clinical Endoscopy, 57(5), 620-627. https://doi.org/10.5946/ce.2023.179
Vancouver
Lim ZH, Seo SI, Myung DS, Kim SH, Lee HH, Kim S, et al. Current status and clinical outcome of endoscopic hemostatic powder in gastrointestinal bleeding: a retrospective multicenter study. Clinical Endoscopy. 2024;57(5):620-627. doi:10.5946/ce.2023.179
BibTeX
@article{Lim2024,
author = {Lim, Zie Hae and Seo, Seung In and Myung, Dae-Seong and Kim, Seung Han and Lee, Han Hee and Kim, Selen and Lee, Bo-In},
title = {Current status and clinical outcome of endoscopic hemostatic powder in gastrointestinal bleeding: a retrospective multicenter study},
journal = {Clinical Endoscopy},
year = {2024},
volume = {57},
number = {5},
pages = {620--627},
doi = {10.5946/ce.2023.179}
}
EUVIMED